Literature DB >> 2446734

Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.

N Panza1, G Pacilio, L Campanella, G Peluso, C Battista, A Amoriello, W Utech, C Vacca, G Lombardi.   

Abstract

Cancer antigen 125 (CA 125) is common to most epithelial ovarian tumors. Therefore, it is potentially a good marker of this disease. This hypothesis was evaluated by measuring the serum levels of CA 125 in 81 patients with ovarian cancer (25 with nonactive and 56 with active disease), in 105 patients of both sexes with nonovarian tumors, and in 171 healthy controls of both sexes. The serum levels of three other markers, tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), and human chorionic gonadotropin, beta subunit (beta-hCG), were also measured in the same 357 subjects. The results of this study clearly indicate the clinical irrelevance of both CEA and beta-hCG as tumor markers in ovarian carcinomas. Conversely, the clinical usefulness of CA 125 and TPA was confirmed. In particular, CA 125 and TPA showed comparable sensitivity, while CA 125 showed a higher specificity for ovarian cancer than TPA. The association of CA 125 with TPA was very useful in continuous observation of patients with active disease in order to evaluate the clinical effectiveness of the therapy. Moreover, for patients in clinical remission, the markers allowed early detection of a recurrence of the disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2446734     DOI: 10.1002/1097-0142(19880101)61:1<76::aid-cncr2820610113>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer.

Authors:  Luis C Fernandes; Su B Kim; Sarhan S Saad; Delcio Matos
Journal:  World J Gastroenterol       Date:  2006-06-28       Impact factor: 5.742

2.  Immunoscintigraphy using CA 125 antibodies in the management of ovarian cancer.

Authors:  J Brökelmann; A Bockisch; J Vogel; J Reinsberg; P Oehr; H J Biersack; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1989       Impact factor: 2.344

3.  Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma.

Authors:  Luís C Fernandes; Su B Kim; Delcio Matos
Journal:  World J Gastroenterol       Date:  2005-02-07       Impact factor: 5.742

4.  (131I)meta-iodobenzylguanidine scintigraphy and selective venous catheterization after thyroidectomy for medullary thyroid carcinoma.

Authors:  G Lupoli; G Lombardi; N Panza; B Biondi; G Pacilio; S Lastoria; M Salvatore
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

5.  Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.

Authors:  M Chigira; T Shinozaki
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

6.  Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy.

Authors:  M K Tuxen; G Sölétormos; P Dombernowsky
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

7.  Performance of seven criteria to assess CA125 increments among ovarian cancer patients monitored during first-line chemotherapy and the post-therapy follow-up period.

Authors:  Suher O Abu Hassan; Dorte L Nielsen; Malgorzata K Tuxen; Per H Petersen; György Sölétormos
Journal:  Future Sci OA       Date:  2017-07-18

8.  Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.

Authors:  Julia Eismann; Yujing J Heng; Johannes M Waldschmidt; Ioannis S Vlachos; Kathryn P Gray; Ursula A Matulonis; Panagiotis A Konstantinopoulos; Charles J Murphy; Sheida Nabavi; Gerburg M Wulf
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-19       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.